FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Asset / Drug

Network-Guided

Drug and asset intelligence for Network-Guided with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Stage: Development stage unavailable

Recent signals(1)

ClinicalJuly 10, 2026

Network-Guided TMS Trial for Alzheimer's Behavioral Symptoms Initiated

A double-blind randomized controlled trial is underway to assess the safety and efficacy of personalized network-guided transcranial magnetic stimulation (TMS) for behavioral and psychological symptoms in Alzheimer's disease.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

Alzheimer's Disease →

Therapeutic areas

Alzheimer's Disease →

Neurology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.